Drug intelligence / Profile preview

BT-001 + pembrolizumab

Development stage: Unknown
Lead developer: Transgene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intra-tumoral (BT-001), Intravenous (pembrolizumab)

Overview

BT-001 + pembrolizumab is a combination investigational therapy consisting of BT-001, a multifunctional oncolytic virus, and pembrolizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. BT-001 is designed to selectively replicate within tumors and release immunomodulatory transgenes, transforming "cold" tumors into "hot" tumors by promoting immune cell infiltration and inducing PD(L)-1 positivity in the tumor microenvironment. Pembrolizumab blocks PD-1 on T cells, inhibiting immune checkpoint signaling and enhancing antitumor immune responses. The combination is being evaluated for patients with metastatic or advanced solid tumors, particularly those unresponsive to previous PD(L)-1 therapies.

Other names: BT-001 + KEYTRUDABT-001 + MK3475

Targets

PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on BT-001 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT-001 + pembrolizumab.

Explore the full profile